CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that Stuart Lee, M.D., Investigator at Vidant Medical Center in Greenville, North Carolina, will be giving an oral platform presentation titled “Histopathology of Necrotic Spinal Cord Tissue Exudate Collected During Surgical Implantation of a Biodegradable Scaffold Following Acute Spinal Cord Injury: Pre-clinical and Clinical Findings” at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting to be held October 7-11, 2017 in Boston, MA. The presentation will be made on Wednesday, October 11, during the Rapid-Exchange Oral Presentations, Session 2.
Dr. Lee said, “The INSPIRE trial has allowed us to gain new insights into acute spinal cord injury pathology. I look forward to sharing these preliminary findings and continuing to explore INSPIRE data.”
“We look forward to interacting with the neurosurgical community attending this important conference, and sharing results from the INSPIRE study that provide new information about the acute phase of spinal cord injury,” Mark Perrin, Chief Executive Officer and Chairman, said.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold™ received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.